A Large, Multinational Drug Corporation Conducts a Phase 1 Clinical

A large, multinational drug corporation conducts a phase 1 clinical trail to evaluate the safety profile and pharmacokinetics properties of a new drug designed to treat refractory epilepsy. Initial studies showed that the drug undergoes extensive metabolism by the liver into glucuronidation byproducts that are primarily excreted by the kidneys. The curve bellow demonstrates the glucuronidation rate of the drug over a wide range of doses.

A) A constant proportion of the drug is metabolized past point 3
B) Bioavailability of the drug is highest at point 1
C) Biotransformation of the drug ceases near point 2
D) Metabolism begins to switch to zero-order kinetics near point 2
E) The rate of drug metabolism is not dependent on dose before point 1